DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies
Novartis
Novartis
National Institutes of Health Clinical Center (CC)
Enterome
University of Avignon
Instituto do Cancer do Estado de São Paulo
University of California, San Francisco
National Cancer Institute (NCI)
Yale University
Vanderbilt-Ingram Cancer Center